Immatics Announces Second Quarter 2026 Financial Results and Business Update

* Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally modeled

* Company plans to proceed directly to a streamlined final analysis for the primary endpoint, PFS, while strengthening power for the secondary endpoint, OS, to enhance the commercial product profile